论文部分内容阅读
目的：测定人肺癌细胞株ＳＫ－ＬＣ－６（大细胞癌）和ＳＫ－ＬＣＤ－７（腺癌）药物ＣＢＤＣＡ、５－Ｆｕ及蒽环类的反应曲线。方法：本研究用体外抗癌药敏试验ＨＴＣＡ和 ＭＴＴ法。结果：在 ＨＴＣＡ中，人肺癌细胞株的克隆形成率 ＰＥ值分为 ０． ４５８０和 ０ ９３００，表明ＨＴＣＡ适于对肺癌细胞进行培养、研究。没类型瘤细胞在ＨＴＣＡ中ＰＥ值不一样，揭示其肿瘤干细胞的生长特性不一样。结果亦表明：１、不同类型肿瘤细胞对同一药物反应性不同显示化疗个体化的必要性。２、同一类型肿瘤细胞对不同药物反应性不一，从而揭示抗癌药敏试验用于临床预测肺癌患者对抗癌药物敏感或耐药是可取的。３、同一类型肺癌对同类抗癌药物反应性相似，通过比较其量效关系曲线可筛选出有效抗癌新药。结论：通过两种方法的对比分析，显示两种方法有较好的相关性，ＨＴＣＡ测试结果稳定、准确，但其耗费大，技术要求高，而ＭＴＴ法操作简单快速、标本可测率高，便于推广，可望为肿瘤患者的治疗提供一定指导。
Objective: To determine the response curves of human lung cancer cell lines SK-LC-6 (large cell carcinoma) and SK-LCD-7 (adenocarcinoma) drugs CBDCA, 5-Fu and anthracycline. Methods: This study used in vitro anticancer drug sensitivity test HTCA and MTT method. Results: In HTCA, the cloning rate of human lung cancer cell lines was divided into 0. 4580 and 0 9300 indicate that HTCA is suitable for the culture and study of lung cancer cells. Different types of tumor cells have different PE values in HTCA, revealing that their tumor stem cells have different growth characteristics. The results also showed that: 1. The different types of tumor cells respond differently to the same drug to show the necessity of individualized chemotherapy. 2. The same types of tumor cells have different reactivity to different drugs, thus revealing that anticancer drug susceptibility test is clinically useful for predicting sensitivity or resistance to anticancer drugs against lung cancer patients. 3. The same type of lung cancer has similar reactivity to similar anti-cancer drugs. By comparing the dose-effect curves, effective anti-cancer drugs can be screened out. Conclusion: The comparison between the two methods shows that the two methods have good correlation. The HTCA test results are stable and accurate, but they are expensive and require high technical requirements. However, the MTT method is simple and rapid, and the testable rate is high. Easy to promote, it is expected to provide some guidance for the treatment of cancer patients.